Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$527K Buy
4,100
+975
+31% +$114K 0.05% 137
2026
Q1
$376K Buy
3,125
+513
+20% +$59.2K 0.04% 163
2025
Q4
$275K Buy
2,612
+78
+3% +$7.32K 0.03% 190
2025
Q3
$213K Buy
+2,534
New +$209K 0.03% 197
2025
Q2
– Sell
-2,701
Closed -$242K – 204
2025
Q1
$242K Buy
2,701
+153
+6% +$14.3K 0.04% 169
2024
Q4
$251K Sell
2,548
-29
-1% -$2.99K 0.04% 161
2024
Q3
$293K Sell
2,577
-22
-0.8% -$2.61K 0.05% 146
2024
Q2
$322K Buy
2,599
+521
+25% +$67.1K 0.06% 136
2024
Q1
$274K Buy
2,078
+13
+0.6% +$1.6K 0.06% 137
2023
Q4
$225K Buy
+2,065
New +$214K 0.05% 148

Other funds holding MRK

Legacy Edge Advisors's MRK Position: Q2 2026 in Review

Legacy Edge Advisors increased its Merck (MRK) stake by 31% in Q2 2026, buying an estimated $114K and bringing the position to 4,100 shares worth $527K. The position accounts for 0.05% of the portfolio, ranked #137.

Legacy Edge Advisors first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. 3,851 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Legacy Edge Advisors held 4,100 shares of Merck worth $527K as of Q2 2026.
  • Legacy Edge Advisors bought 975 Merck shares in Q2 2026, an estimated $114K.
  • Merck made up 0.05% of Legacy Edge Advisors's portfolio in Q2 2026, its #137 holding.
  • Legacy Edge Advisors first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • 3,851 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Legacy Edge Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.